Диссертация (1139780), страница 20
Текст из файла (страница 20)
Med. PR - 1998 - Vol. 83P.181-184.144.Braham C., Fraiture A.L. Banal dermatomycosis that cannot be overlooked //Rev. Med. Lieg. - 2001. - Vol. 56 - P.6.145.Braham C., Ezzine - Sebai N., et al. The connection between sports andspores. The foot, its mycoses and onychomycosis // Rev. Med. Lieg. - 2001. Vol. 56 - P.6.146.Brautigam M., Nolting S., Schopf R.E., Weidinger G.
Randomized doubleblind comparison of terbinafine and itraconazole for treatment of toenail tineainfection // Br. Med. J. - 1999 - Vol. 311- P. 22.147.Brooks C., Kujawska A., Patel D. Cutaneous allergic reactions induced by 20sporting activities // Sports Med. - 2003 - Vol. 33.148.Bokhari M.A., Hussain I., Jahangir M., Haroon T.S., Aman S., Khurshid K.Onychomycosis in Lahore, Pakistan // Ind. J.
Dermatol. - 1999. - Vol. 38,№8. - P. 591-595.149.Brun S., Bouchara J. P., Basile A.M., Bocquel A., Contet - Audonneau N.,Chabasse D. Evaluation of five commercial Sabouraud gentamicinchloramphnicol agar media // Eur. J. Clin. Microbiol. Infect. Dis. - 2001. Vol. 20 - P.23.132150.Burzykowski T., Molenberghs G., et al. High prevalence of foot diseases inEurope: results of the Achilles Project // Mycoses - 2003. - Vol. 46. - P. 496 505.151.Caputo R., De Boulle K., Prevalence of superficial fungal infections amongsports-active individuals: results from the Achilles survey, a review of theliterature // J. Eur.
Acad. Dermatol. Venerol. - 2001. - Vol. 15 - P.6.152.Carney C., Cantrell W., Warner J., Elewski B. Treatment of onychomycosisusing a submillisecond 1064-nm neodymium: yttrium-aluminum-garnet laser// J.Am. Acad. Dermatol.- 2013 Oct;69 (4): 578-82. doi:10.1016/j.jaad.2013.04.054. Epub 2013 Jul 13.153.Chabasse D. Can we evaluate the frequency of onychomycosis? // Ann.Dermatol. Venerol. - 2003. - Vol.130 - P.30.154.Chacon A., Franca K, Fernandez A., Nouri K. Psychosocial impact ofonychomycosis: a review // Int. J. Dermatol.
2013; 52(11): 1300–1307.155.Chan M.K. and Chong L.Y. A prospective epidemiologic survey on theprevalence of foot disease in Hong Kong // J. Am. Podiatr Med. Assoc. 2002. - Vol. 92. - P. 6.156.Chokoeva A.A., Tchernev G., Patterson J.W., Lotti T., Wollina U.. Lifethreatening onychomycosis imitator // J.
Biol. Regul. Homeost. Agents. - 2015– Jan - Mar; 29 (1 Suppl): 31-2.157.Cohen A.D., Medvesovsky E., Shalev R. An independent comparison ofterbinafine and itraconazole in the treatment of toenail onychomycosis // J.Dermatolog Treat.
– 2003. Dec 14; (4): 237–242.158.Davis R., Balfour J.A. Terbinafine: pharmacoeconomic evaluation of its usein superficial fungal infections // Pharmacoeconomics – 1995. – Vol. 8 – P.69.159.De Backer M., De Keyser P., Massart D. L., Westelinck K. J. Terbinafine(Lamisil) 250 mg/day and 500 mg/ day are equally effective in a 16 week oraltreatment of toenail onychomycosis: a double –blind multicenter trial.
In: HayRJ, editor. International perspective on Lamisil. London, UK: CCT HealthcareCommunications; - 1994. - P. 39 - 43.133160.De Hoog G. S., Guarro J., Gene J., Figueras M.J. Atlas of clinical fungi.2nded. Utrecht/Reus: Centralbureau voor Schimmelcultures // universitat Roviari Virgili, - 2002. - P. 1126.161.Detandt M., Nolard N. Fungal contamination of the doors of swimming pools,particularly subtropical swimming paradises // Mycoses - 1995.
- Vol. 38. - P.509-513.162.Dawson B., and Trapp R. G. Basic and clinical biostatistics. McGraw-Hill,Singapore, Malaysia -2001. - Vol.3 - P.146-147.163.Dobrovwolska A., Staczek P., Kaszuba A., and Kozlowska M. PCR-RFLPanalysis of the dermatophytes isolated from patients in Central Poland // J.Dermatol.
Sci. - 2006. - Vol.42. - P.71-74.164.Denning D.W., Evans E.G.V., Kibbler C.C., Richardson M.D., Roberts M.M.,Rogers T.R.,Warnock D.W., and Warren R.E. Fungal nail disease: a guide togood practice (report of a Working Group of the British Society for MedicalMycology) // Br. Med.J. - 1998. - Vol. 311. - P.1277 - 1281.165.Diongue K., Diallo M.A., Badiane A.S., Seck M.C., Ndiaye M., Ndoye N.W.,Ndiaye Y.D., Dieye B., Déme A., Ndiaye I.M., Ndir O., Ndiaye D.Nondermatophytic and noncandidal fungi isolated in Le Dantec Universityhospital of Dakar in 2014: Epidemiological, clinical and mycological study //J.Mycol.Med.-2015Sep;25(3):181-90.doi:10.1016/j.mycmed.2015.05.003.
Epub 2015 Jun 29.166.Effendy, I., Lecha M., Epidemiology and clinical classification ofonychomycosis // J. Eur. Acad. Dermatol. Venereol. – 2005. –Vol. 19. – P. 812.167.Elewski B.E. Onychomycosis: Pathogenesis, Diagnosis, and Management //Clin. Microbiol. – 1998.
- Vol.11. - P.415 - 429.168.Elewski B.E., Leyden J., Rinaldi M.G., Atillasoy E. Office practice-basedconfirmation of onychomycosis: a US nationwide prospective survey // Arch.Intern. Med. - 2002. -Vol.162. - P.8.134169.Elewski B.E., Tosti A. Risk Factors and Comorbidities for Onychomycosis:Implications for Treatment with Topical Therapy // J. Clin. Aesthet. Dermatol.- 2015. - Nov; 8(11):38-42.170.Elewski B., Pariser D., Rich Ph., Scher R.K.
Current and Emerging Options inthe Treatment of Onychomycosis // Semin. Cutan. Med. Surg. - 2013; 32 (2,Suppl 1): S9–S12.171.El-Tatawy R.A., Abd El-Naby N.M., El-Hawary E.E., Talaat R.A. Acomparative clinical and mycological study of Nd-YAG laser versus topicalterbinafine in the treatment ofonychomycosis // J. Dermatol. Treat. -2015 Oct;26(5): 461-4. doi: 10.3109/09546634.2014.998607. Epub 2015 Feb 11.172.Escobar M.L. and Carmona- Fonseca J. Onychomycosis by common non –dermatophyte moulds.
Rev Iberoam Micol - 2003. - Vol.20. - P.6-10.173.Ellis D., Marley J., Watson A.B. Non-dermatophytes in onychomycosis of thetoenails // Br.J. Dermatol. - 1997. -Vol.136, №4. - P. 490 - 493.174.Evans D.T. double blind, randomized study of continuous terbinafinecompared with intermittent itraconazole in treatment of onychomycosis // Br.Med. J - 1999. - Vol.318. - P.1031 -1035.175.Faergemann J., and Baran R. Epidemiology, clinical presentation anddiagnosis of onychomycosis. Br. J. Dermatol. - 2003.-Vol.149 – P.1- 4.176.Fernandez -Torres B., Vazquez - Veiga H., Llovo X., Pereiro M Jr., GuarroJ.In vitro susceptibility to itraconazole, clotrimazole, ketoconazole andterbinafine of 100 isolates of Trichophyton rubrum // Chemother.
- 2000.Nov.- Dec.- Vol. 46, №6. - P.390 - 394.177.Frankum L.E., Nightengale B., Russo C.L., Sarnes M. Pharmacoeconomicanalysis of sequential treatment path-ways in the treatment of onychomycosis// Managed care interface. - 2005; 18: 55–63178.Galvan Garcia H.R., Onychomycosis: 1064-nm Nd:YAG q – switch lasertreatment // J. Cosmet. Dermatol. - 2014 Sep; - 13 (3): 232-5. doi:10.1111/jocd.12102.135179.Ginarte M., Garcia - Doval I., et al. Observer agreement in toenail disorders:implications for diagnosis and clinical research // Br. J.
Dermatol. - 2009. Vol. 160. - P.7.180.Guibal F., R. Baran. Epidemiology and management of onychomycosis inprivate dermatological practice in France // Ann Dermatol Venereol -2008. Vol.135. - P.6.181.Guillot J., Latie L., Deville M., Halos L., Chermette r. Evaluation of thedermatophyte test medium // RapidVet. - D.Vet Dermatol. - 2001. - Vol.12. P.7.182.Gupta A.K., Paque M. A retrospective chart review of the clinical efficacy ofNd:YAG 1064-nm laser for toenail onychomycosis // J. Dermatolg.
Treat.2015; 26(4):376-8. doi: 10.3109/09546634.2014.975671. Epub 2014 Nov 5.183.Gupta A.K., Ryder J.E., Baran R. The use of topical therapies to treatonychomycosis // Dermatol. Clin. – 2003. - Vol 21. P. 481-9.184.Gupta A.K., Simpson FC. Laser therapy for onychomycosis // J Cutan MedSurg. 2013 - Sep-Oct; 17 (5): 301-7.185.Gupta A.K., Simpson F.C., Heller D.F. The future of lasers in onychomycosis// J. Dermatolog Treat.– 2016.
-Mar; 27(2): 167-72. doi:10.3109/09546634.2015.1066479. Epub 2015 Aug 13.186.GuptaA.K.,StudholmeC.Novelinvestigationaltherapiesforonychomycosis: an update // Expert Opin Investig Drugs. – 2016 Mar; 25 (3):297-305. doi: 10.1517/13543784.2016.1142529.187.Hay R. Literature review. Onychomycosis // J.
Eur. Acad. Dermatol.Venereol. - 2009. - Vol. 19. - P. 1 - 7.188.Harris M.D., McDowell B.A., Strisower J. Laser treatment of toenail fungus //Photonic Therapeutics and Diagnostics. – Feb. 19, 2009.189.Hochman L.G. Laser treatment of onychomycosis using a novel 0,65 –millisecond pulsed Nd:YAG 1064 nm laser // Journal of Cosmetic and LaserTherapy. - 2011 - Vol.13 - P. 2-5.136190.Hees H., Jager MW., Raulin C. Treatment of onychomycosis using the 1064nm Nd:YAG laser: a clinical pilot study // J Dtsch Dermatol. 2014 Apr; 12(4):322-9.
doi: 10.1111/ddg.12292. Epub 2014 Mar 14.191.Hees H., Raulin C., Baumler W. Laser treatment of onychomycosis: an invitro pilot study // J. Dtsch. Dermatol. Ges. 2012 Dec; 10 (12): 913-8. doi:10.1111/j.1610-0387.2012.07997.x. Epub 2012 Aug 1.192.Helou J., Maatouk I., Hajjar MA., Moutran R. Evaluation of Nd:YAG laserdevice efficacy on onychomycosis: a case series of 30 patients // Mycoses. 2016 - Jan; 59 (1): 7-11. doi: 10.1111/myc.12425. Epub 2015 Nov 5.193.Ibrahim O., Doumit J., Zhang A. Successful Treatment of IdiopathicOnychodystrophy With 300 Microsecond 1064 nm Nd:YAG Laser // J.
DrugsDermatol. - 2015 - Jul; 14 (7): 750-2.194.Kalokasidis K., Onder M., Trakatelli MG., Richert B., Fritz K. The Effect ofQ-SwitchedNd:YAG1064 nm/532 nmLaserintheTreatmentofOnychomycosis In Vivo // Dermatol. Res Pract. 2013; 2013:379725. doi:10.1155/2013/379725. Epub 2013 Dec 14.195.Kolodchenko Y.V., Baetul V.I. A Novel Method for the Treatment of FungalNail Disease with 1064 nm Nd:YAG // Journal of the Laser and HealthAcademy - Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
